secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2026-09-23T21:20:22+00:00
Accession:  0001683168-26-007340
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic-Santersus share exchange values combined company at $141M; XBIO holders ~15%
--------------------------------------------------------------------------------

- Deal values Xenetic at ~$21M (15% pro forma) and Santersus at ~$120M (85%); 2,546,699 XBIO shares outstanding.
- Expected to close Q4 2026; combined company to trade on Nasdaq under ticker SNTS.
- NucleoCapture holds two FDA Breakthrough Device Designations; 80+ compassionate-use cases showed positive outcomes with no adverse events.
- Lead sepsis program (~$5.6B market) targets potential EU launch in Q2 2028; CAR T lymphoma efficacy data expected Q2 2027.
- Santersus options assumed by Xenetic; $0 net cash assumed, subject to adjustment per Share Exchange Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316826007340/0001683168-26-007340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316826007340/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer